Mifepristone: a potential contraceptive.
Use of standard estrogen-progestin contraception remains problematic in several subgroups of patients (e.g., those in whom exogenous estrogens are contraindicated, such as survivors of hormone-dependent cancer, or patients with endometriosis or uterine fibroids). In addition, the postcoital contraception, even if already available, remains at least underused. Additionally, continuous intake of contraceptive steroids is under increasing scrutiny. Would antiprogestins, and specifically the applications of mifepristone such as the ones reviewed in this article offer significant improvements at such problematic occasions? The most attractive novel contraceptive application of mifepristone is that of emergency postcoital contraception after unprotected intercourse. In addition, various options in the endometrial category, specifically those requiring drug administration only during a limited time, might be used in the future. Mifepristone might offer contraceptive and therapeutic relief to patients suffering from endometriosis or uterine fibroids, both conditions that have been shown to benefit from mifepristone therapy. However, the use of mifepristone in contraceptive preparations that are widely available would pose an additional problem of possible misuse of the compound, the reason for currently limiting access to mifepristone. However, such risk should be easily avoidable in the case of postcoital contraception in which only one dose of mifepristone is needed. Regarding the future of mifepristone, and more broadly that of antiprogestins in contraception, the authors believe that they will have a place in the future contraceptive armament. As already emphasized, the strongest clinical areas are those of immediate postcoital and endometrial contraception. Additional studies evaluating parenteral modes of administration, the long-term endometrial effects, and safety and metabolic effects of prolonged antiprogestin administration are needed before mifepristone can be considered a part of the contraceptive arena.
Heikinheimo
O
O
University of Helsinki, Finland.
Archer
D F
DF
D003270:Contraceptive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003281:Contraceptives, Postcoital / Q000008:administration & dosage / Q000494:pharmacology; D004717:Endometrium / Q000187:drug effects; D005260:Female; D006801:Humans; D008600:Menstruation-Inducing Agents / Q000008:administration & dosage / Q000494:pharmacology; D015735:Mifepristone / Q000008:administration & dosage / Q000494:pharmacology*; D010060:Ovulation / Q000187:drug effects
D003270:Contraceptive Agents; D003281:Contraceptives, Postcoital; D008600:Menstruation-Inducing Agents; D015735:Mifepristone